Prescient Therapeutics (ASX:PTX) received a fast-track designation from the US Food and Drug Administration for its PTX-100 compound for the potential treatment of adults with relapsed or refractory mycosis fungoides, according to a Wednesday filing with the Australian bourse.
The designation will expedite the review of therapies for serious conditions with high unmet need, enabling earlier delivery to patients, the filing said.
Mycosis fungoides is a subtype of cutaneous T-cell lymphoma, a group of rare blood cancers affecting the skin.
Shares rose nearly 5% in afternoon trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.